Join to View Full Profile
2020 Santa Monica Blvd., Suite 600Santa Monica, CA 90404
Phone+1 310-570-1472
Fax+1 310-570-1472
Dr. Wainberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2000 - 2003
Tel Aviv University SacklerClass of 2000
Certifications & Licensure
CA State Medical License 2003 - 2027
NY State Medical License 2001 - 2003
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Start of enrollment: 2007 Dec 01
- Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer Start of enrollment: 2009 Sep 01
- Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.Shen Zhao, Ying Cheng, Qiming Wang, Xingya Li, Jun Liao
Nature Medicine. 2025-04-10 - S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE).Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, Dan G Duda, Robin Park
Future Oncology. 2025-03-28 - Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies.Yelena Y Janjigian, Michael Cecchini, Kohei Shitara, Peter C Enzinger, Zev A Wainberg
JCO Precision Oncology. 2025-03-01
Journal Articles
- Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-Line, Advanced Gastric CancerAl Benson, Zev A Wainberg, JAMA Oncology
Lectures
- First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC).ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase ...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) can...2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Press Mentions
AACR: Topical Treatment Offers Relief from Painful Skin Rash Caused by Targeted Cancer TherapyApril 25th, 2025- Liposomal Irinotecan for Pancreatic Cancer: Is It Worth It?May 22nd, 2024
- NALIRIFOX Changes Care in Pancreatic Cancer: Here’s HowFebruary 16th, 2023
- Join now to see all
Grant Support
- Causes and Consequences of Adenosine Signaling in Pancreatic CancerUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2029
- Causes and Consequences of Adenosine Signaling in Pancreatic CancerUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2029
- Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancerUNIVERSITY OF CALIFORNIA LOS ANGELES2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
